Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHOC 2022 | Using CEC levels to evaluate treatment outcomes of splanchnic vein thrombosis in chronic MPNs

Alessandro Lucchesi • 12 Oct 2022
EHOC 2022
Myeloproliferative Neoplasms Hydroxyurea Ruxolitinib

Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of a study which used circulating endothelial cells (CECs) to evaluate treatment outcomes of splanchnic vein thrombosis in patients with chronic myeloproliferative neoplasms (MPNs). This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandro Lucchesi

1:08
Insights into disease-modifying agents being explored in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:24
Understanding aberrant signaling pathways to prevent resistance to JAK2 inhibitors in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:00
A novel model being used to investigate thrombo-inflammation in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:47
Investigating the role of thrombo-inflammation in MPNs
Alessandro Lucchesi • 12 Oct 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals